MabCampath-1h

Phase 3

Sanofi (SNY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsing Remitting Multiple Sclerosis

View Full Landscape

Drug Information

Target Indication

Relapsing Remitting Multiple Sclerosis

Clinical Trial

NCT01307332

Last updated: 8/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/6/2001

MabCampath

MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts